Product Name |
CDK1 |
CDK2 |
CDK3 |
CDK4 |
CDK5 |
CDK6 |
CDK7 |
CDK8 |
CDK9 |
CDK11 |
CDK12 |
CDK13 |
CDK14 |
CDK16 |
CDK19 |
CDC |
CLK |
Purity |
Palbociclib |
|
|
|
Cdk4/cyclin D3, IC50: 9 nM
Cdk4/cyclin D1, IC50: 11 nM
|
|
Cdk6/cyclin D2, IC50: 16 nM
|
|
|
|
|
|
|
|
|
|
|
|
≥95.0% |
Palbociclib monohydrochloride |
|
|
|
Cdk4/cyclin D3, IC50: 9 nM
Cdk4/cyclin D1, IC50: 11 nM
|
|
Cdk6/cyclin D2, IC50: 16 nM
|
|
|
|
|
|
|
|
|
|
|
|
≥95.0% |
Abemaciclib |
CDK1/cyclinB1, IC50: 1627 nM
|
CDK2/cyclinE, IC50: 504 nM
|
|
Cdk4/cyclin D1, IC50: 2 nM
|
CDK5/p35, IC50: 287 nM
Cdk5/p25, IC50: 355 nM
|
CDK6/cyclinD1, IC50: 10 nM
|
CDK7/Mat1/cyclinH1, IC50: 3910 nM
|
|
CDK9/cyclinT1, IC50: 57 nM
|
|
|
|
|
|
|
|
|
99.69% |
Dinaciclib |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.36% |
Ribociclib |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
KB-0742 dihydrochloride |
|
|
|
|
|
|
|
|
CDK9/cyclinT1, IC50: 6 nM
|
|
|
|
|
|
|
|
|
99.63% |
JH-XI-10-02 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.18% |
hSMG-1 inhibitor 11j |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.91% |
Abemaciclib methanesulfonate |
CDK1/cyclinB1, IC50: 1627 nM
|
CDK2/cyclinE, IC50: 504 nM
|
|
Cdk4/cyclin D1, IC50: 2 nM
|
Cdk5/p25, IC50: 355 nM
CDK5/p35, IC50: 287 nM
|
CDK6/cyclinD1, IC50: 10 nM
|
CDK7/Mat1/cyclinH1, IC50: 3910 nM
|
|
CDK9/cyclinT1, IC50: 57 nM
|
|
|
|
|
|
|
|
|
≥98.0% |
THZ1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥98.0% |
THZ531 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.86% |
Ro-3306 |
CDK1, Ki: 20 nM
CDK1/cyclinB1, Ki: 35 nM
CDK1/cyclin A, Ki: 110 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.54% |
Flavopiridol |
|
|
|
CDK4/Cyc D1, IC50: 100 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.72% |
Seliciclib |
cdc2/cyclin B, IC50: 0.65 μM
|
cdk2/cyclin A, IC50: 0.7 μM
Cdk2/cyclin E2, IC50: 0.7 μM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥98.0% |
AZD4573 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
PF-06873600 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.98% |
Palbociclib isethionate |
|
|
|
Cdk4/cyclin D3, IC50: 9 nM
Cdk4/cyclin D1, IC50: 11 nM
|
|
Cdk6/cyclin D2, IC50: 16 nM
|
|
|
|
|
|
|
|
|
|
|
|
99.96% |
SR-4835 |
|
|
|
|
|
|
|
|
|
|
CDK12, IC50: 99 nM
CDK12, Kd: 98 nM
|
|
|
|
|
|
|
98.46% |
NVP-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥98.0% |
CYC065 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.78% |
Simurosertib |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.07% |
SNS-032 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.50% |
AZD-5438 |
cdk1-cyclin B1, IC50: 16 nM
|
cdk2-cyclin E, IC50: 6 nM
cdk2-cyclin A, IC50: 45 nM
|
|
cdk4-cyclin D1, IC50: 449 nM
|
|
cdk6-cyclin D3, IC50: 21 nM
|
cdk7-cyclin H, IC50: 821 nM
|
|
cdk9-cyclin T, IC50: 20 nM
|
|
|
|
|
|
|
|
|
99.37% |
AT7519 |
Cdk1/cyclin B, IC50: 210 nM
|
cdk2/cyclin A, IC50: 47 nM
|
|
Cdk4/cyclin D1, IC50: 100 nM
|
|
cdk6/cyclin D3, IC50: 170 nM
|
CDK7/Cyclin H/MAT1, IC50: 2400 nM
|
|
CDK9/Cyclin T, IC50: 10 nM
|
|
|
|
|
|
|
|
|
99.40% |
Zotiraciclib |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.96% |
Flavopiridol Hydrochloride |
|
|
|
CDK4/Cyc D1, IC50: 100 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥95.0% |
GSK 3 Inhibitor IX |
Cdk1/cyclin B, IC50: 320 nM
|
cdk2/cyclin A, IC50: 300 nM
|
|
Cdk4/cyclin D1, IC50: 10 μM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥98.0% |
Ribociclib succinate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.52% |
OTS964 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.32% |
JNJ-7706621 |
Cdk1/cyclin B, IC50: 9 nM
|
CDK2/cyclinE, IC50: 3 nM
cdk2/cyclin A, IC50: 4 nM
|
CDK3/Cyclin E, IC50: 58 nM
|
Cdk4/cyclin D1, IC50: 253 nM
|
|
CDK6/cyclinD1, IC50: 175 nM
|
|
|
|
|
|
|
|
|
|
|
|
99.96% |
Samuraciclib hydrochloride |
|
cdk2/cyclin A, IC50: 578 nM
|
|
|
CDK5/p35NCK, IC50: 9.4 μM
|
|
CDK7/cyclin H, IC50: 41 nM
|
|
|
|
|
|
|
|
|
|
|
99.98% |
Kenpaullone |
Cdk1/cyclin B, IC50: 0.4 μM
|
cdk2/cyclin A, IC50: 0.68 μM
CDK2/cyclinE, IC50: 7.5 μM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥97.0% |
THZ1 Hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.49% |
AUZ 454 |
|
CDK2(C118L/A144C), Kd: 9.7 nM
CDK2(A144C), Kd: 15.4 nM
CDK2(C118L), Kd: 18.6 nM
CDK2(WT), Kd: 50 nM
CDK2(C118L/A144C-Cyclin B), Kd: 134.1 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.99% |
BSJ-03-123 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.45% |
CCT-251921 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.77% |
XL413 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.72% |
Senexin A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
Mevociclib |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.27% |
MBQ-167 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.67% |
BI-1347 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.83% |
CVT-313 |
Cdk1/cyclin B, IC50: 4.2 μM
|
cdk2/cyclin A, IC50: 0.5 μM
|
|
Cdk4/cyclin D1, IC50: 215 μM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.76% |
Wogonin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.98% |
TG003 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CLK1, IC50: 20 nM
CLK2, IC50: 200 nM
Clk4, IC50: 15 nM
|
99.13% |
CGP60474 |
CDK1-Cyclin B, IC50: 26 nM
|
CDK2/cyclinE, IC50: 3 nM
cdk2/cyclin A, IC50: 4 nM
|
|
CDK4/cyclin D, IC50: 216 nM
|
|
|
CDK7/cyclin H, IC50: 200 nM
|
|
|
|
|
|
|
|
|
|
|
98.70% |
AS2863619 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥98.0% |
Milciclib |
cyclin B/CDK1, IC50: 398 nM
|
cyclin A/CDK2, IC50: 45 nM
cyclin E/CDK2, IC50: 363 nM
|
|
cyclin D1/CDK4, IC50: 160 nM
|
|
|
cyclin H/CDK7, IC50: 150 nM
|
|
|
|
|
|
|
|
|
|
|
99.92% |
LDC4297 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.14% |
YKL-5-124 TFA |
|
|
|
|
|
|
CDK7, IC50: 53.5 nM
CDK7/Mat1/CycH, IC50: 9.7 nM
|
|
|
|
|
|
|
|
|
|
|
|
(+)-BAY-1251152 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.66% |
THZ2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥95.0% |
BMS-265246 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.28% |
R547 |
Cdk1/cyclin B, Ki: 2 nM
Cdk1/cyclin B, IC50: 0.2 nM
|
CDK2/cyclinE, Ki: 3 nM
cdk2/cyclin A, IC50: 0.1 nM
CDK2/cyclinE, IC50: 0.4 nM
|
CDK3/Cyclin E, IC50: 0.8 nM
|
|
|
cdk6/cyclin D3, IC50: 4 nM
|
CDK7/cyclin H, IC50: 171 nM
|
|
|
|
|
|
|
|
|
|
|
99.66% |
CLK-IN-T3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CLK1, IC50: 0.67 nM
CLK2, IC50: 15 nM
CLK3, IC50: 110 nM
|
98.40% |
Ribociclib hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
CLK1-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.03% |
LDC000067 |
cdk1-cyclin B1, IC50: 5513 nM
|
cdk2-cyclin A, IC50: 2441 nM
|
|
cdk4-cyclin D1, IC50: 9242 nM
|
|
|
|
|
CDK9- Cyclin T1, IC50: 44 nM
|
|
|
|
|
|
|
|
|
98.58% |
NG 52 |
cdc2-cyclin B, IC50: 0.34 μM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.97% |
KH-CB19 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CLK1, IC50: 19.7 nM
CLK3, IC50: 530 nM
|
99.66% |
Purvalanol A |
cdc2-cyclin B, IC50: 4 nM
|
cdk2-cyclin E, IC50: 35 nM
cdk2-cyclin A, IC50: 70 nM
|
|
cdk4-cyclin D1, IC50: 850 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.11% |
Roniciclib |
Cdk1/cyclin B, IC50: 7 nM
|
|
|
CDK4/cyclin D, IC50: 11 nM
|
|
|
CDK7/Cyclin H/MAT1, IC50: 25 nM
|
|
CDK9/cyclinT1, IC50: 5 nM
|
|
|
|
|
|
|
|
|
98.89% |
SEL120-34A monohydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK19/CycC, IC50: 10.4 nM
|
|
|
99.98% |
PHA-767491 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.91% |
MSC2530818 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.69% |
Trilaciclib hydrochloride |
|
|
|
Cdk4/cyclin D1, IC50: 1 nM
|
|
cdk6/cyclin D3, IC50: 4 nM
|
|
|
|
|
|
|
|
|
|
|
|
99.24% |
CDK2-IN-4 |
Cdk1/cyclin B, IC50: 86 μM
|
cdk2/cyclin A, IC50: 44 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥97.0% |
PHA-793887 |
Cdk1/cyclin B, IC50: 60 nM
|
cdk2/cyclin A, IC50: 8 nM
CDK2/cyclinE, IC50: 8 nM
|
|
Cdk4/cyclin D1, IC50: 62 nM
|
|
|
CDK7/cyclin H, IC50: 10 nM
|
|
CDK9/cyclinT1, IC50: 138 nM
|
|
|
|
|
|
|
|
|
99.25% |
(R)-CR8 trihydrochloride |
CDK1/cyclinB1, IC50: 0.09 μM
|
cdk2/cyclin A, IC50: 0.072 μM
CDK2/cyclinE, IC50: 0.041 μM
|
|
|
|
|
CDK7/cyclin H, IC50: 1.1 μM
|
|
CDK9/Cyclin T, IC50: 0.18 μM
|
|
|
|
|
|
|
|
|
99.02% |
CDK12-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.22% |
PF 477736 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.21% |
Atuveciclib |
CDK1/CycB(h), IC50: 1100 nM
|
CDK2/CycE(h), IC50: 1000 nM
|
CDK3/CycE(h), IC50: 890 nM
|
|
CDK5/p35(h), IC50: 1600 nM
|
|
|
|
CDK9/CycT1, IC50: 13 nM
CDK9/CycT1(h), IC50: 6 nM
|
|
|
|
|
|
|
|
|
99.20% |
ON123300 |
|
|
|
Cdk4/cyclin D1, IC50: 3.9 nM
|
|
CDK6/cyclinD1, IC50: 9.82 nM
|
|
|
|
|
|
|
|
|
|
|
|
98.52% |
SU9516 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.83% |
ML167 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clk4, IC50: 136 nM
CLK1, IC50: 1522 nM
CLK2, IC50: 1648 nM
|
98.62% |
LY2857785 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.88% |
Cucurbitacin E |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
FMF-04-159-2 |
|
CDK2, IC50: 256 nM (in NanoBRET assay)
|
|
|
|
|
|
|
|
|
|
|
CDK14/Cyclin Y, IC50: 39.6 nM (in NanoBRET assay)
|
|
|
|
|
99.34% |
BS-181 |
|
CDK2/Cyc E, IC50: 0.88 μM
|
|
|
|
|
CDK7/CycH/MAT1, IC50: 0.021 μM
|
|
|
|
|
|
|
|
|
|
|
98.10% |
FN-1501 |
|
cdk2/cyclin A, IC50: 2.47 nM
|
|
Cdk4/cyclin D1, IC50: 0.85 nM
|
|
CDK6/cyclinD1, IC50: 1.96 nM
|
|
|
|
|
|
|
|
|
|
|
|
98.41% |
CC-671 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.86% |
CDK9-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.48% |
Purvalanol B |
cdc2/cyclin B, IC50: 6 nM
cyclin dependent kinase 1-cyclinB, IC50: 6 nM
|
cdk2/cyclin A, IC50: 6 nM
CDK2/cyclinE, IC50: 9 nM
|
|
Cdk4/cyclin D1, IC50: 10000 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥97.0% |
CP-10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.03% |
Riviciclib hydrochloride |
CDK1-Cyclin B, IC50: 0.079 μM
|
cdk2-cyclin A, IC50: 0.224 μM
cdk2-cyclin E, IC50: 2.500 μM
|
|
cdk4-cyclin D1, IC50: 0.063 μM
|
|
cdk6-cyclin D3, IC50: 0.396 μM
|
|
|
CDK9- Cyclin T1, IC50: 0.020 μM
CDK9-cyclin H, IC50: 2.900 μM
|
|
|
|
|
|
|
|
|
98.33% |
CDK-IN-2 |
|
|
|
|
|
|
|
|
CDK9/cyclinT1, IC50: 8 nM
|
|
|
|
|
|
|
|
|
98.82% |
LY3177833 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.78% |
Abemaciclib metabolite M20 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.24% |
Longdaysin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
ON-013100 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.23% |
PROTAC CDK9 Degrader-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.34% |
Bisindolylmaleimide X hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.53% |
Abemaciclib metabolite M2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.82% |
AT7519 Hydrochloride |
Cdk1/cyclin B, IC50: 210 nM
|
cdk2/cyclin A, IC50: 47 nM
|
|
Cdk4/cyclin D1, IC50: 100 nM
|
|
cdk6/cyclin D3, IC50: 170 nM
|
CDK7/Cyclin H/MAT1, IC50: 2400 nM
|
|
CDK9/Cyclin T, IC50: 10 nM
|
|
|
|
|
|
|
|
|
99.99% |
Atuveciclib Racemate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥98.0% |
CDK12-IN-E9 |
|
cdk2/cyclin A, IC50: 932 nM
|
|
|
|
|
CDK7/Cyclin H/MNAT1, IC50: 1210 nM
|
|
CDK9/cyclinT1, IC50: 23.9 nM
|
|
|
|
|
|
|
|
|
99.20% |
CDK5 inhibitor 20-223 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.64% |
CDKI-73 |
CDK1, IC50: 8.17 nM
CDK1, Ki: 4 nM
|
CDK2, IC50: 3.27 nM
CDK2, Ki: 3 nM
|
|
|
|
|
CDK7, IC50: 134.26 nM
CDK7, Ki: 91 nM
|
|
CDK9, IC50: 5.78 nM
CDK9, Ki: 4 nM
|
|
|
|
|
|
|
|
|
99.58% |
(-)-BAY-1251152 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.82% |
AMG 925 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.33% |
(R)-CR8 |
Cdk1/cyclin B, IC50: 0.09 μM
|
cdk2/cyclin A, IC50: 0.072 μM
CDK2/cyclinE, IC50: 0.041 μM
|
|
|
|
|
CDK7/cyclin H, IC50: 1.1 μM
|
|
CDK9/Cyclin T, IC50: 0.18 μM
|
|
|
|
|
|
|
|
|
≥98.0% |
BS-181 hydrochloride |
|
CDK2/Cyc E, IC50: 0.88 μM
|
|
|
|
|
CDK7/CycH/MAT1, IC50: 0.021 μM
|
|
|
|
|
|
|
|
|
|
|
≥99.0% |
MC180295 |
CDK1-Cyclin B, IC50: 138 nM
|
cdk2-cyclin A, IC50: 233 nM
cdk2-cyclin E, IC50: 367 nM
|
CDK3-Cyclin E, IC50: 399 nM
|
CDK4-Cyclin D, IC50: 112 nM
|
cdk5-p35, IC50: 159 nM
cdk5-p25, IC50: 186 nM
|
cdk6-cyclin D3, IC50: 712 nM
|
CDK7-CycH/MAT1, IC50: 555 nM
|
|
CDK9- Cyclin T1, IC50: 5 nM
|
|
|
|
|
|
|
|
|
98.47% |
Voruciclib hydrochloride |
CDK1/cycB, Ki: 5.4 nM
CDK1/cyc A, Ki: 9.1 nM
|
|
|
|
|
|
|
|
CDK9/CycT1, Ki: 1.68 nM
CDK9/cyc T2, Ki: 0.626 nM
|
|
|
|
|
|
|
|
|
98.20% |
AS2863619 free base |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥98.0% |
Lerociclib dihydrochloride |
CDK1/cyclinB1, IC50: 2.4 μM
|
cdk2/cyclin A, IC50: 1.5 μM
CDK2/cyclinE, IC50: 3.6 μM
|
|
Cdk4/cyclin D1, IC50: 1 nM
|
CDK5/p35, IC50: 832 nM
Cdk5/p25, IC50: 1.2 μM
|
cdk6/cyclin D3, IC50: 2 nM
|
CDK7/Cyclin H/MAT1, IC50: 2.4 μM
|
|
CDK9/Cyclin T, IC50: 28 nM
|
|
|
|
|
|
|
|
|
98.45% |
CKI-7 free base |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.31% |
PNU112455A hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.62% |
Ribociclib succinate hydrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.96% |
CDK9-IN-7 |
|
|
|
CDK4/cyclin D, IC50: 148 nM
|
|
CDK6/cyclinD, IC50: 145 nM
|
|
|
CDK9/cyclinT1, IC50: 11 nM
|
|
|
|
|
|
|
|
|
99.81% |
SEL120-34A HCl |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK19/CycC, IC50: 10.4 nM
|
|
|
99.98% |
K00546 |
Cdk1/cyclin B, IC50: 0.6 nM
|
cdk2/cyclin A, IC50: 0.5 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CLK1, IC50: 8.9 nM
CLK3, IC50: 29.2 nM
|
98.78% |
LSN3106729 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.01% |
BSJ-04-132 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.08% |
CDK9-IN-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.06% |
JSH-150 |
Cdk1/cyclin B, IC50: 1.34 μM
|
cdk2/cyclin A, IC50: 2.86 μM
|
|
|
|
|
CDK7/Cyclin H/MNAT1, IC50: 1.72 μM
|
|
CDK9/cyclinT1, IC50: 1 nM
|
|
|
|
CDK14/Cyclin Y, IC50: 1.68 μM
|
CDK16/Cyclin Y, IC50: 292 nM
|
|
|
|
98.36% |
Garcinone C |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥95.0% |
NU2058 |
|
CDK2, IC50: 17 μM
CDK2, Ki: 12 μM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.01% |
BSJ-03-204 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.34% |
Voruciclib |
CDK1/cycB, Ki: 5.4 nM
CDK1/cyc A, Ki: 9.1 nM
|
|
|
|
|
|
|
|
CDK9/cyc T2, Ki: 0.626 nM
CDK9/CycT1, Ki: 1.68 nM
|
|
|
|
|
|
|
|
|
99.52% |
Alsterpaullone |
Cdk1/cyclin B, IC50: 35 nM
|
cdk2/cyclin A, IC50: 15 nM
CDK2/Cyc E, IC50: 200 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥98.0% |
BRD6989 |
|
|
|
|
|
|
|
CDK8, IC50: ~200 nM
recombinant CDK8, IC50: ~0.5 μM
|
|
|
|
|
|
|
recombinant CDK19, IC50: >30 μM
|
|
|
99.85% |
Olomoucine |
|
cdk2-cyclin A, IC50: 7 μM
cdk2-cyclin E, IC50: 7 μM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥98.0% |
BGG463 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥98.0% |
NVP-LCQ195 |
Cdk1/cyclin B, IC50: 2 nM
|
cdk2/cyclin A, IC50: 2 nM
CDK2/cyclinE, IC50: 5 nM
|
CDK3/Cyclin E, IC50: 42 nM
|
|
Cdk5/p25, IC50: 1 nM
CDK5/p35, IC50: 1 nM
|
cdk6/cyclin D3, IC50: 187 nM
|
CDK7/Cyclin H/MAT1, IC50: 3564 nM
|
|
CDK9/cyclinT1, IC50: 15 nM
|
|
|
|
|
|
|
|
|
99.80% |
CDK7-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.91% |
CAN508 |
Cdk1/cyclin B, IC50: 44 μM
|
CDK2/cyclinE, IC50: 20 μM
cdk2/cyclin A, IC50: 69 μM
|
|
Cdk4/cyclin D1, IC50: 13.5 μM
|
|
|
CDK7/cyclin H, IC50: 26 μM
|
|
CDK9/cyclinT1, IC50: 0.35 μM
|
|
|
|
|
|
|
|
|
|
PROTAC CDK2/9 Degrader-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NU6140 |
CDK1-Cyclin B, IC50: 6.6 μM
|
cdk2-cyclin A, IC50: 0.41 μM
|
|
CDK4-Cyclin D, IC50: 5.5 μM
|
|
|
cdk7-cyclin H, IC50: 3.9 μM
|
|
|
|
|
|
|
|
|
|
|
≥99.0% |
CDK4/6-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.82% |
NU6102 |
Cdk1/cyclin B, IC50: 9.5 nM
|
CDK2/cyclin A3, IC50: 5.4 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥95.0% |
Palbociclib D8 |
|
|
|
Cdk4/cyclin D3, IC50: 9 nM
Cdk4/cyclin D1, IC50: 11 nM
|
|
Cdk6/cyclin D2, IC50: 16 nM
|
|
|
|
|
|
|
|
|
|
|
|
99.84% |
FIT-039 |
|
|
|
|
|
|
|
|
CDK9/cyclinT1, IC50: 5.8 μM
|
|
|
|
|
|
|
|
|
≥98.0% |
AMG 925 HCl |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.01% |
5-Iodo-indirubin-3'-monoxime |
Cdk1/cyclin B, IC50: 25 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.50% |
SEL120-34A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK19/CycC, IC50: 10.4 nM
|
|
|
|
Desmethylglycitein |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≥95.0% |
XL413 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AT7519 trifluoroacetate |
Cdk1/cyclin B, IC50: 210 nM
|
cdk2/cyclin A, IC50: 47 nM
|
|
Cdk4/cyclin D1, IC50: 100 nM
|
|
cdk6/cyclin D3, IC50: 170 nM
|
CDK7/Cyclin H/MAT1, IC50: 2400 nM
|
|
CDK9/Cyclin T, IC50: 10 nM
|
|
|
|
|
|
|
|
|
98.16% |
PHA-767491 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK4/6-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
FN-1501-propionic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK8/19-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK19/CycC, IC50: 0.99 nM
|
|
|
|
CDK9-IN-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PROTAC CDK9 degrader-2 |
|
|
|
|
|
|
|
|
CDK9, IC50: 17 μM (MCF-7 cells)
|
|
|
|
|
|
|
|
|
|
IIIM-290 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Riviciclib |
CDK1-Cyclin B, IC50: 0.079 μM
|
cdk2-cyclin A, IC50: 0.224 μM
cdk2-cyclin E, IC50: 2.540 μM
|
|
cdk4-cyclin D1, IC50: 0.063 μM
|
|
cdk6-cyclin D3, IC50: 0.396 μM
|
|
|
CDK9- Cyclin T1, IC50: 0.020 μM
CDK9-cyclin H, IC50: 2.900 μM
|
|
|
|
|
|
|
|
|
|
TL12-186 |
|
cdk2/cyclin A, IC50: 73 nM
|
|
|
|
|
|
|
CDK9/cyclinT1, IC50: 55 nM
|
|
|
|
|
|
|
|
|
|
OTS964 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK6/9-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Lerociclib |
CDK1/cyclinB1, IC50: 2.4 μM
|
cdk2/cyclin A, IC50: 1.5 μM
CDK2/cyclinE, IC50: 3.6 μM
|
|
Cdk4/cyclin D1, IC50: 1 nM
|
CDK5/p35, IC50: 0.832 μM
Cdk5/p25, IC50: 1.2 μM
|
cdk6/cyclin D3, IC50: 2 nM
|
CDK7/Cyclin H/MAT1, IC50: 2.4 μM
|
|
CDK9/Cyclin T, IC50: 28 nM
|
|
|
|
|
|
|
|
|
|
CDK7-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BS-181 dihydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CKI-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NU6027 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK9-IN-11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Bohemine |
|
CDK2/cyclinE, IC50: 4.6 μM
cdk2/cyclin A, IC50: 83 μM
|
|
|
|
|
|
|
CDK9/cyclinT1, IC50: 2.7 μM
|
|
|
|
|
|
|
|
|
≥98.0% |
Cdk1/2 Inhibitor III |
Cdk1/cyclin B, IC50: 2.1 μM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
YKL-5-124 |
|
|
|
|
|
|
CDK7, IC50: 53.5 nM
CDK7/Mat1/CycH, IC50: 9.7 nM
|
|
|
|
|
|
|
|
|
|
|
|
Nimbolide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Indirubin-3'-monoxime-5-sulphonic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Indirubin-5-sulfonate |
Cdk1/cyclin B, IC50: 55 nM
|
cdk2/cyclin A, IC50: 35 nM
CDK2/cyclinE, IC50: 150 nM
|
|
Cdk4/cyclin D1, IC50: 300 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK9-IN-10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
hSMG-1 inhibitor 11e |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|